Primary Outcome
Of all patients who underwent VIT, 338 (25.2%) took β-blockers and/or ACEI. Only 19 (5.6%) of patients, who were taking β-blockers or ACEI, experienced a systemic AE compared to 74 (7.4%) of patients not taking such drugs resulting in an odds ratio (OR) of 0.74 (95% confidence interval (CI): 0.43–1.22, p=0.25; Table 3). In detail, 4 of 123 (3.3%) had systemic AE taking β-blockers, 13 of 157 (8.3%) experienced systemic AE under ACEI treatment, and 2 of 58 (3.5%) had systemic AE taking β-blockers and ACEI (p=0.15). All systemic AE in patients with antihypertensive treatment were mild to moderate reactions. The most severe reaction occurred in a patient not taking AHT drugs (Table 2).